GARDASIL 9 40 MCG / 0.5 ML
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN : 40 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 58 L1 PROTEIN : 20 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEIN : 30 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN : 40 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 33 L1 PROTEIN : 20 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN : 20 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN : 20 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN : 60 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 45 L1 PROTEIN : 20 MCG / 0.5 ML · DIN 02437058 · MERCK CANADA INC
Health Canada status: MARKETED
What is GARDASIL 9?
GARDASIL 9 40 MCG / 0.5 ML contains RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN : 40 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 58 L1 PROTEIN : 20 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEIN : 30 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN : 40 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 33 L1 PROTEIN : 20 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN : 20 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN : 20 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN : 60 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 45 L1 PROTEIN : 20 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02437058, held by MERCK CANADA INC, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 18-Mar-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02437058 |
|---|---|
| Brand name | GARDASIL 9 |
| Generic / active ingredient | RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN : 40 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 58 L1 PROTEIN : 20 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEIN : 30 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN : 40 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 33 L1 PROTEIN : 20 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN : 20 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN : 20 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN : 60 MCG / 0.5 ML RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 45 L1 PROTEIN : 20 MCG / 0.5 ML |
| Manufacturer | MERCK CANADA INC |
| Strength | 40 MCG / 0.5 ML |
| Dosage form | SUSPENSION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07BM03 PAPILLOMAVIRUS (HUMAN TYPES 6,11,16,18,31,33,45,52,58) |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Mar-2015 |
| Original market date | 2015-03-18 00:00:00 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.